Abbott and Novo Nordisk partner to launch Extensior for diabetes care in India

India’s diabetes challenge is growing fast, and access to modern treatment options matters more than ever. In a new move aimed at improving care, Abbott has partnered with Novo Nordisk India to bring Extensior, a semaglutide-based therapy, to Indian patients. The medicine is based on semaglutide, the same molecule used in Ozempic, and is designed for adults with type 2 diabetes.

Through this collaboration, Abbott will commercialise Extensior in India, combining Novo Nordisk’s expertise in GLP-1 science with Abbott’s wide reach across the country.

WHAT THE PARTNERSHIP MEANS

Under the agreement, Novo Nordisk will develop and manufacture semaglutide, while Abbott will handle its commercial



presence in India under the brand name Extensior.

The aim is simple: help more people with type 2 diabetes access evidence-based treatment options that go beyond basic blood sugar control.

This collaboration brings together Novo Nordisk’s long-standing work in GLP-1 therapies and Abbott’s strong on-ground presence in India, especially in diabetes medicines, diagnostics and nutrition.

Extensior will be part of Abbott’s expanding advanced diabetes portfolio and is expected to be available to Indian patients soon.

The launch is positioned as a step towards wider access to modern diabetes therapies in a country with one of the highest diabetes burdens globally.